IMMX · Immix Biopharma, Inc. · Debt
$8.05
-0.01 (-0.12%)
At close · Oct 27
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 7, 2026
Substantial doubt about the company's ability to continue as a going concern.
“The Company is unable to entirely fund these efforts with its current financial resources. If adequate funds are unavailable on a timely basis from operations or additional sources of financing, the Company may have to delay, reduce the scope of or eliminate one or more of its research or development programs which may materially and adversely affect its business, financial condition and operations.”View the 10-Q filed Aug 7, 2026
Market Cap
$576.61M
Shares
71.54M
Volume · Oct 27
1.15M
Avg daily vol (3M)
1.54M
Debt Profile
Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.
Reported debt balances
Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.
| Reported balance | As of | Amount | Source |
|---|---|---|---|
| Operating lease liabilities | 2026-06-30 | USD 1,001,752 | 10-Q filed 2026-08-07 |
Related accounting measures — not additional borrowingCarrying amounts can reflect issuance costs or discounts. Differences between these measures are not necessarily repayments due within a year.
| |||
Instrument and agreement coverage is incomplete. Additional filings are awaiting review.
Covenants
Covenant terms have not yet been verified for this profile.
The balance figures do not establish whether covenants apply or whether the company complies with them.
Loans, facilities and notes
The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.
Key facts
CIK
1873835
CUSIP
45258H106
13F (30d)
12 filings
12 filers
Visit website
Investor relations